Related Experiment Video
Updated: May 22, 2025

Detection and Visualization of DNA Damage-induced Protein Complexes in Suspension Cell Cultures Using the Proximity Ligation Assay
Published on: June 9, 2017
Targeting DNA damage sensors for cancer therapy
Matthew R Jordan1, Pamela L Mendoza-Munoz1, Katherine S Pawelczak2
1Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.
Abstract:
DNA damage occurs from both endogenous and exogenous sources and DNA damaging agents are a mainstay in cancer therapeutics. DNA damage sensors (DDS) are proteins that recognize and bind to unique DNA structures that arise from direct DNA damage or replication stress and are the first step in the DNA damage response (DDR). DNA damage sensors are responsible for recruiting transducer proteins that signal downstream DNA repair pathways. As the initiating proteins, DDS are excellent candidates for anti-cancer drug targeting to limit DDR activation. Here, we review four major DDS: PARP1, RPA, Ku, and the MRN complex. We briefly describe the cellular DDS functions before analyzing the structural mechanisms of DNA damage sensing. Lastly, we examine the current state of the field towards inhibiting each DDS for anti-cancer therapeutics and broadly discuss the therapeutic potential for DDS targeting.
Insights
DNA damage sensors (DDS) initiate the DNA damage response (DDR) by recognizing DNA damage. Targeting DDS like PARP1, RPA, Ku, and MRN offers a promising strategy for novel anti-cancer therapeutics.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Therapeutics
Background:
- DNA damage, from internal and external sources, is a critical factor in cancer development.
- DNA damage sensors (DDS) are crucial proteins that initiate the DNA damage response (DDR) by detecting DNA lesions.
- DDS proteins recruit downstream signaling molecules, orchestrating DNA repair pathways.
Purpose of the Study:
- To review the functions and structural mechanisms of four key DNA damage sensors: PARP1, RPA, Ku, and the MRN complex.
- To analyze the current landscape of targeting these DDS for anti-cancer drug development.
- To discuss the therapeutic potential of inhibiting DDS in cancer treatment.
Main Methods:
- Literature review of cellular functions of major DDS.
- Analysis of structural mechanisms underlying DNA damage recognition by DDS.
- Examination of current research on DDS inhibition for anti-cancer therapies.
Main Results:
- PARP1, RPA, Ku, and the MRN complex are identified as critical DDS initiating the DDR.
- Understanding the structural basis of DNA damage sensing by these proteins is key to developing targeted inhibitors.
- Several DDS are actively being pursued as targets for novel anti-cancer drugs.
Conclusions:
- DNA damage sensors are pivotal in the DDR and represent viable targets for cancer therapy.
- Inhibiting specific DDS can disrupt cancer cell proliferation and survival.
- Targeting DDS holds significant therapeutic potential for developing new anti-cancer strategies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
DNA Damage can Stall the Cell Cycle
Overview of DNA Repair
Chemically...
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
DNA Damage Can Stall the Cell Cycle
Treatment Resistant Cancers

